Latest News

Covagen Secures CHF 42 Million in Series B Financing.

ZURICH-SCHLIEREN, Switzerland, Dec. 9, 2013 - Covagen today announced that the company has secured CHF 42 million in a tranched Series B financing with an option to obtain an additional CHF 14 million that would increase the total amount of the financing round to CHF 56 million. This is one of the largest private financing rounds for a preclinical-stage biotech company in. ...


Tanabe Research Laboratories and Mitsubishi Tanabe Pharma Nominate First Bispecific FynomAb® for Preclinical Development and Exercise an Option for a Second Bispecific FynomAb Program

November 21st, 2013, Switzerland and San Diego – Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed...


MIMICS Emerging Data Suggest Patency Protective Effect

Las Vegas, USA, 9 October 2013 – Data presented here yesterday during the Late Breaking Clinical Trials session at VIVA13 show that a stent with unique three dimensional helical geometry, BioMimics 3D™, developed by Veryan Medical Ltd., (Horsham, UK), a portfolio company of Seroba Kernel Life Sciences, has demonstrated safety and promising clinical performance at twelve months...


< back to home page